Corbin Capital Partners’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Corbin Capital Partners’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-464,062	Closed	-$29.7K	–	106
2022 Q4	$29.7K	Hold	464,062	–	–	0.01%	67
2022 Q3	$28K	Hold	464,062	–	–	0.01%	81
2022 Q2	$42K	Hold	464,062	–	–	0.01%	89
2022 Q1	$111K	Hold	464,062	–	–	0.02%	95
2021 Q4	$306K	Hold	464,062	–	–	0.05%	79
2021 Q3	$306K	Hold	464,062	–	–	0.06%	74
2021 Q2	$399K	Sell	464,062 -154,687	-25%	-$108K	0.08%	64
2021 Q1	$371K	Buy	+618,749	New	+$436K	0.09%	53

Corbin Capital Partners's BIOTW Position: Q1 2023 in Review

Corbin Capital Partners sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 464,062 shares — an estimated $29.7K sold.

Corbin Capital Partners first reported a position in BIOTW in Q1 2021 and held it in 8 quarters. The position peaked at $399K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Corbin Capital Partners reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Corbin Capital Partners sold 464,062 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $29.7K.
Corbin Capital Partners first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 8 quarters.
Corbin Capital Partners's Biotech Acquisition Company Warrant position peaked at $399K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Corbin Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.